Clinical characterization of stomatitis cases with an EGFR inhibitor in metastatic colorectal cancer patients: A study of 7 cases and literature review

Published:January 17, 2023DOI:



      The aim of this study was to report a case series of metastatic colorectal cancer (mCRC) patients undergoing panitumumab-containing regimens affected by oral lesions and to review the current literature

      Study design

      Electronic medical records of mCRC patients referred to treat mouth sores during the treatment with the anti-EGFR – panitumumab – were retrospectively reviewed. Patients’ characterization, clinical profile of oral lesions and management outcomes were documented. Additionally, modifications or discontinuation of the antineoplastic treatment as well as the occurrence of other adverse events (AEs) were analyzed


      A total of 7 patients were included. The oral lesions appeared in a median time of 10 days (range 7-11 days) following the drug administration. Median reported pain score was 5 (range 1-9), causing feeding discomfort. Oral lesions with a marked aphthous-like appearance, among others, occurred in all cases and involved nonkeratinized mucosa more likely. At least 1 patient had dose reduction of the treatment and 1 patient needed discontinuation due to panitumumab-associated stomatitis. Dermatologic AEs were the most prevalent. Clinical improvement was obtained with topical corticosteroid therapy and/or photobiomodulation


      In summary, panitumumab-containing regimes were associated with a particular pattern of oral lesions consistent with stomatitis. This event may eventually affect the tolerability of the treatment in mCRC patients.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'